Clinical Trials on Coagulation in United Kingdom

Total 926 results

NHS Lothian

Unknown

Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Device Compared With Laboratory Assay

Blood Coagulation Tests

United Kingdom
Baxalta now part of Shire

Terminated

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Hemophilia

United Kingdom
Royal Free Hospital NHS Foundation Trust

Unknown

Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B (InPath)

Haemophilia

United Kingdom
Hampshire Hospitals NHS Foundation Trust

Completed

National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A (UK-PK)

Hemophilia A

United Kingdom
Great Ormond Street Hospital for Children NHS Foundation...
University College, London

Completed

What is the Feasibility of the ISTEP Exercise Test in Boys With Haemophilia

Hemophilia

United Kingdom
Hampshire Hospitals NHS Foundation Trust
Uppsala University; University of Wales Cardiff United Kingdom (UK)

Completed

Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

Severe Haemophilia A

United Kingdom
Haemnet
BioMarin Pharmaceutical

Completed

Learning to Live With Non-severe Haemophilia

Hemophilia

United Kingdom
East Kent Hospitals University NHS Foundation Trust

Not yet recruiting

Virtual Evaluations of Joint Health Using Wearable Sensors in Persons With Haemophilia (VESPA) (VESPA)

Haemophilia

United Kingdom
Haemnet
Hemab ApS

Recruiting

The Lived Experience of People With Von Willebrand Disease (VWD360)

Von Willebrand Diseases

United Kingdom
Haemnet
UniQure Biopharma B.V.

Completed

An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their Families (Exigency)

Hemophilia

United Kingdom
Bio Products Laboratory

Completed

A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years

Factor X Deficiency

United Kingdom
Haemnet
Roche Chugai

Completed

An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families (EmiandMe)

Hemophilia A With Inhibitor

United Kingdom
East Kent Hospitals University NHS Foundation Trust
Great Ormond Street Hospital for Children NHS Foundation Trust; University...

Recruiting

Trial of an Exercise Intervention for Children With Haemophilia (DOLPHIN-II)

Hemophilia | Musculoskeletal Diseases or Conditions | Child, Only

United Kingdom
University College, London

Recruiting

Liver Biopsy In Haemophilia Gene Therapy

Hemophilia A, Severe | Hemophilia B, Severe

United Kingdom
Novo Nordisk A/S

Enrolling by invitation

Adverse Event Data Collection From External Registries on Nonacog Beta Pegol

Haemophilia B

Netherlands, United Kingdom
Pfizer

Completed

Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

Hemophilia A

United Kingdom, Hungary, Bulgaria
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Haemophilia A Patients (270-201)

Severe Haemophilia A

United Kingdom
Cangene Corporation

Withdrawn

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Hemophilia B

United Kingdom, United States
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

Haemophilia B

United Kingdom
Cwm Taf University Health Board (NHS)
Cardiff Metropolitan University

Recruiting

Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke (PREDICT-EV)

Transient Ischemic Attack | Coagulation Disorder | Stroke, Ischemic

United Kingdom
Novo Nordisk A/S

Completed

Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
University College, London
Medical Research Council

Recruiting

Gene Therapy for Haemophilia A. (GO-8)

Hemophilia A

United States, United Kingdom
Novo Nordisk A/S

Completed

Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Bio Products Laboratory

Terminated

Optivate in People With Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

Israel, United Kingdom
Bio Products Laboratory

Terminated

A Study With OPTIVATE® in People With Von Willebrand Disease

Von Willebrand Disease

Israel, United Kingdom
Baxalta now part of Shire

Terminated

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Hemophilia A

United States, South Africa, United Kingdom
Eli Lilly and Company
Sigilon Therapeutics, Inc.

Terminated

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Hemophilia A

United Kingdom, United States
Haemnet
Hemab ApS

Completed

The Experiences of People Who Live With Glanzmanns Thrombasthenia.

Glanzmann Thrombasthenia

United Kingdom
Novo Nordisk A/S

Completed

A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A

Congenital Bleeding Disorder | Haemophilia A

United Kingdom, Malaysia
ApcinteX Ltd
Centessa Pharmaceuticals plc

Active, not recruiting

The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B)

Hemophilia A | Hemophilia B

Georgia, Moldova, Republic of, United Kingdom
Freeline Therapeutics

Terminated

A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy

Hemophilia B

United Kingdom
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B

Haemophilia B

United Kingdom
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

BAX 855 Dose-Escalation Safety Study

Hemophilia A

Japan, Bulgaria, Germany, United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

Haemophilia B

United Kingdom, Poland
Bio Products Laboratory

Terminated

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery (Ten03)

Factor X Deficiency

United Kingdom, United States, Spain, Turkey
Bayer

Completed

Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors (MATCHBOX)

Hemophilia A | Hemophilia B

South Africa, Poland, United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Freeline Therapeutics

Terminated

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Hemophilia B

United States, United Kingdom
Vega Therapeutics, Inc

Recruiting

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease

Von Willebrand Diseases

United States, Austria, South Africa, United Kingdom
CSL Behring

Completed

Study of Voncento® in Subjects With Von Willebrand Disease

Von Willebrand Disease

Poland, Germany, Austria, Greece, United Kingdom
Ultragenyx Pharmaceutical Inc

Completed

Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Hemophilia B

United States, United Kingdom
UMC Utrecht

Unknown

Cardiovascular Disease (CVD) in Haemophilia

Cardiovascular Disease | Haemophilia

Netherlands, United Kingdom
CSL Behring

Completed

Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)

Coagulation Protein Disorders | Perioperative Care | Blood Loss, Surgical

United Kingdom
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
St. Jude Children's Research Hospital
Children's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

Hemophilia B

United States, United Kingdom
Medexus Pharma, Inc.

Terminated

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Hemophilia B

United States, United Kingdom, India
BioMarin Pharmaceutical

Enrolling by invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401) (GENEr8-LTE)

Hemophilia A

United Kingdom, United States
University College, London

Terminated

A Factor IX Gene Therapy Study (FIX-GT) (FIX-GT)

Hemophilia B

Ireland, United Kingdom, Italy, United States

Clinical Trials on Coagulation in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations